Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -0.27%91 Days Payable is 174.34 as of Mar. 2026, which is 511% above its 10-year median of 28.54. GuruFocus rates XPAE:BPC with a GF Score™ of 91/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 72.92% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's Days Payable falls into.
Birzeit Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Birzeit Pharmaceutical Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a Days Payable of 174.34 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Birzeit Pharmaceutical Co and its competitors. This is 511% above median its historical median of 28.54. Over the past decade, Birzeit Pharmaceutical Co's Days Payable has ranged from 16.91 to 150.29. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #251 out of 927 companies in the Drug Manufacturers industry, placing it in the top 27.1%.
Is Birzeit Pharmaceutical Co's Days Payable too high?
Birzeit Pharmaceutical Co's current Days Payable of 174.34 is 511% above median its 10-year median of 28.54. Over the past 10 years, this metric has ranged from a low of 16.91 to a high of 150.29. The Drug Manufacturers industry median Days Payable is 90.38. Birzeit Pharmaceutical Co's value of 174.34 is 92.9% above this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #251 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #251 out of 927 companies for Days Payable. This puts Birzeit Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 90.38. Birzeit Pharmaceutical Co's value of 174.34 is 92.9% above this benchmark. Historically, Birzeit Pharmaceutical Co's own Days Payable has ranged from 16.91 to 150.29 over the past decade. While the company's 10-year median is 28.54 vs. the industry median of 90.38, Birzeit Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current Days Payable of 174.34 is 92.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current Days Payable is 174.34, which is 511% above median its own 10-year median of 28.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.67 — trading 20% below its estimated fair value. The current Days Payable is 174.34, which is 511% above median its 10-year median of 28.54 and 92.9% above the Drug Manufacturers industry median of 90.38. Birzeit Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current Days Payable is 174.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.67 is trading 20% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
Days Payable: 174.34 (511% above median its 10-year median of 28.54)
GF Value™: $4.59 vs. price of $3.67 (20% below fair value)
Industry Position: 92.9% above the Drug Manufacturers median (#251 of 927)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
91GF Score
Get the complete analysis for XPAE:BPC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
